Novo Nordisk A/S (NONOF)
Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
As of 09:34AM EDT. Market open.
| Previous close | 127.72 |
| Open | 127.00 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 127.00 - 130.94 |
| 52-week range | 74.70 - 140.32 |
| Volume | |
| Avg. volume | 28,954 |
| Market cap | 576.48B |
| Beta (5Y monthly) | 0.19 |
| PE ratio (TTM) | 45.26 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.86 (1.46%) |
| Ex-dividend date | 22 Mar 2024 |
| 1y target est | N/A |
- Investor's Business Daily
Is Eli Lilly Stock A Buy Or A Sell As FDA Plans Meeting To Discuss Alzheimer's Drug?
Eli Lilly stock broke out, but then slumped. The FDA is soon to hold a meeting to discuss its Alzheimer's drug. Is LLY stock a buy or a sell?
- Barrons.com
Novo Nordisk Sets Sights on a Long-Lasting Successor to Its Weight Loss Blockbuster
The company will collaborate with a biotech founded by Flagship Pioneering, the venture capital firm that created Moderna.
- Zacks
Wall Street Bulls Look Optimistic About Novo Nordisk (NVO): Should You Buy?
According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?
© 2024 Yahoo. All rights reserved.